In recent works it was shown (Logue et al., 2018; Ullo and Logue, 2018) that Src inhibitor Dasatinib, approved by FDA for the treatment of chronic myeloid leukemia, reduced focal adhesions, led to the reduction of cortex actin density and provoked blebbing in melanoma A375 cells. The gene discussed is SRC; the disease is melanoma.